ABSTRACT: Although interaction of a few G protein-coupled receptors (GPCRs) with Filamin A, a key actin cross-linking and biomechanical signal transducer protein, has been observed, a comprehensive structure−function analysis of this interaction is lacking. Through a systematic sequence-based analysis, we found that a conserved filamin binding motif is present in the cytoplasmic domains of >20% of the 824 GPCRs encoded in the human genome. Direct high-affinity interaction of filamin binding motif peptides of select GPCRs with the Ig domain of Filamin A was confirmed by nuclear magnetic resonance spectroscopy and isothermal titration calorimetric experiments. Engagement of the filamin binding motif with the Filamin A Ig domain induced the phosphorylation of filamin by protein kinase A in vitro. In transfected cells, agonist activation as well as constitutive activation of representative GPCRs dramatically elicited recruitment and phosphorylation of cellular Filamin A, a phenomenon long known to be crucial for regulating the structure and dynamics of the cytoskeleton. Our data suggest a molecular mechanism for direct GPCR−cytoskeleton coupling via filamin. Until now, GPCR signaling to the cytoskeleton was predominantly thought to be indirect, through canonical G protein-mediated signaling cascades involving GTPases, adenylyl cyclases, phospholipases, ion channels, and protein kinases. We propose that the GPCR-induced filamin phosphorylation pathway is a conserved, novel biochemical signaling paradigm.
G protein-coupled receptors (GPCRs) initiate wide-ranging responses, including integrin-regulated processes such as cell migration, cell survival, growth, chemotaxis, and the associated cell morphological changes such as membrane ruffling, formation of filopodia, focal adhesions, and formation of lamellipodia.
1,2 These fundamental changes in cells are contingent upon engaging cytoskeletal proteins upon activating the conventional G protein-dependent and -independent signaling mechanisms involving proteins such as β-arrestin, small GTPases, and PDZ-containing proteins. 3 At a molecular level, cell morphological changes or cytoskeletal responses to GPCRs are thought to be an indirect outcome of signaling cascades, and as a consequence, direct binding and activation of a major cytoskeletal protein by GPCRs are not considered a mechanism at present. Biophysical and biochemical studies presented here indicate that a substantial number of GPCRs may directly bind and activate a major actin cross-linking protein, Filamin A (FLNa), and that the binding triggers filamin phosphorylation by cellular protein kinases.
The relationship between GPCRs and cytoskeletal modulation of cellular phenotype is widely evident in physiological and pathological paradigms. Apart from their well-established role as transducers of neuro-endocrine hormone and sensory signals, 4 GPCRs are expressed at high levels in some breast, 5 gynecological, 6 neurological, 7 and prostate cancers 8 and alter invasive properties of tumor cells. 9 Indeed, GPCR blockade is currently being explored as a cancer therapy, and a majority of drugs used in clinical practice are ligands for GPCRs.
Filamin is an actin binding dimeric cytoskeletal protein with 24 immunoglobulin (Ig) repeats that engages the cytoplasmic regions of many transmembrane proteins.
11,12 A few genetic and biochemical studies have reported interaction of GPCRs with FLNa. In these studies, the role of FLNa in augmenting the membrane expression, subcellular localization, trafficking, and signaling of GPCRs is emphasized. For example, intracellular loop 3 (ICL3) of D2 and D3 dopamine receptors was shown to interact with immunoglobulin-like repeat (Ig) 19 of FLNa to promote proper cell surface expression and signaling. 13−15 The C-terminal tail (Ct) of the calcitonin receptor and C−C chemokine receptor type 2 were shown to interact with FLNa Ig20−21 and Ig21−24, respectively, and play key roles in endocytic sorting and internalization of the receptor. 16, 17 Similarly, the interactions of the μ-type opioid receptor with FLNa Ig24, 18−20 the calcium-sensing receptor with FLNa Ig14−15, 21−26 metabotropic glutamate receptor subtype 7b with FLNa Ig21−22, and somatostatin receptor type 2 with FLNa Ig19−20 are reported to play scaffolding and functional roles in GPCR signaling. 27−30 Filamin is a key mediator of epithelial defense against intrusion of transformed cells; 31 therefore, GPCR signal regulation through FLNa is an important unexplored mechanism.
FLNa Ig4, Ig9, Ig12, Ig17, Ig19, Ig21, and Ig23 are class A repeats that possess a conserved binding site capable of engaging several proteins such as platelet glycoprotein Ib α (GPIbα), integrins, and migfilin. 32 Recently, these repeats have been shown to reduce the level of integrin activation when overexpressed in a platelet integrin model through a two-site binding mechanism. 33 Among the class A repeats, Ig21 was shown to have the highest binding affinity for the filamin ligands. 32 Interestingly, Ig21 exists in an autoinhibited form by engaging the N-terminal portion of the Ig20 repeat as an intramolecular inhibitory ligand. 34 Recruitment of filamin binding proteins such as integrins and migfilin to filamin relieves this autoinhibition and promotes structural reorganization of filamin. 35 Recently, it has been revealed that disrupting the Ig21 autoinhibition by FLNa ligands promoted protein kinase A (PKA)-dependent phosphorylation of the S2152 site 36,37 on Ig20. Ligand-dependent S2152 phosphorylation by a variety of FLNa ligands may be a novel pathway for activating filamin function in diverse filamin-mediated cellular processes.
Overall, the current scientific literature suggests the potential involvement of GPCRs in the engagement of different FLNa Ig repeats during a variety of biological responses. Nevertheless, the mechanisms for direct communication between GPCRs and FLNa remain poorly defined at the molecular level. In this study, we found that >20% of human GPCRs are endowed with a likely FLNa binding motif (FBM). We demonstrate highaffinity physical interaction of predicted FBMs for three different GPCRs with FLNa Ig21: (i) angiotensin II type 1 receptor (AT1R), a prototypical agonist-activated GPCR with important roles in cardiovascular physiology, (ii) protooncogene MAS, a constitutively active GPCR with a cardioprotective role, and (iii) α 1D -adrenoreceptor (α 1D -AR), a neurohormone GPCR with cardiovascular roles. As a consequence of high-affinity binding, we demonstrate enhanced PKA-mediated filamin phosphorylation of Ig16−24 in vitro. We further determined that GPCRs, AT1R, and MAS directly recruited FLNa and promoted its phosphorylation by cellular S/T kinases in an agonist-dependent manner. Our studies thus provide a structural framework for filamin in GPCR signaling, potentially regulating a variety of cellular responses.
■ EXPERIMENTAL PROCEDURES
Peptides and Reagents. The following peptides were synthesized by the Biotechnology Core at the Lerner Research Institute of the Cleveland Clinic: (1) D3R, VRKLSNGRLST-SLKLGPLQPRGV; (2) MAS, KKKRFKESLKVVLTRAFK; (3) AT1R, LGKKFKRYFLQLLKYIPPKA; and (4) α 1D -AR, KGH-TFRSSLSVRLLKFSR. All peptides were purified via highperformance liquid chromatography and were >95% pure. Peptide concentrations were estimated using their predicted extinction coefficient at A 280 using the protein parameters tool on the ExPASY server (http://web.expasy.org/pro/). In cases where the peptide did not have a UV signature, the thoroughly lyophilized peptide was weighed carefully and an 85% purity was assumed to estimate concentration.
Human Filamin A (Uniprot entry P21333) immunoglobulin domains Ig16−24 (1772−2647), Ig19 and Ig21 were cloned into pGST-parallel vectors and purified as described previously. 32, 35 Phospho-Filamin A (S2152, #4761) and Filamin A (#4762) polyclonal antibodies were obtained from Cell Signaling Technology (Danvers, MA), while the antibody for GAPDH was obtained from Life Technologies (Grand Island, NY). Filamin A monoclonal antibody for detecting immunoprecipitated filamin was from Millipore (MAB1680). Agonist peptide angiotensin II (AngII) for stimulation was purchased from Bachem, and AT1R antagonist candesartan was a gift from AstraZeneca. Specific MAS activating and inhibiting ligands AR234960 (AR-agonist) and AR244555 (AR-inverse), respectively, were unrestricted gifts from Arena Pharmaceuticals, Inc. (San Diego, CA). PKA inhibitor H-89 was purchased from Sigma-Aldrich (St. Louis, MO). MAS ligands and other inhibitors were dissolved in dimethyl sulfoxide as 10 mM stocks. The pH of the buffer in the experiments was verified to be neutral (7−7.5) after the ligands had been added to the desired concentrations of 10−50 μM.
Identifying the Filamin Class A Repeat Binding Motif (FBM) in GPCRs. On the basis of the sequence alignment of peptides from peptide-bound filamin structures [Protein Data Bank (PDB) entries 2BRQ, 2J3S, 2K9U, 2W0P, 2BP3, 2JF1, and 3ISW], homologous sequences, and the predicted alignment of peptides from a previous study, 38 we rationally defined the FBM as [
, or L, ζ = S, T, N, or Q, X represents any amino acid, X −a represents any amino acid except acidic residues (D and E), and X′ represents any amino acid except P. In the FBM, the position (denoted as subscripts) of the most conserved residue is numbered "0" and usually contains a basic residue (K or R). In addition, in migfilin and CFTR peptidebound filamin structures, we observed that the lack of basic residues at position 0 (underlined residues) appears to be compensated at position −2 or −3. The basic residues at these positions appear to be important for interactions of the peptide with FLNa Ig21, which has a complementary acidic patch. Therefore, in our search algorithm, we introduced the following additional conditions for residues at positions −2 and −3: (1) the presence of K or R is a must in case they are absent at position 0, and (2) no acidic residue (D or E) is allowed. Furthermore, at positions −2 through 6, the residue P was avoided as it is not a preferred residue in a β-strand. A curated list of G protein-coupled receptors (GPCRs) was downloaded from the UniProt Knowledgebase. 39 All 824 human GPCR Biochemistry Accelerated Publication sequences in this list were scanned for (i) the FBM without any mismatches and (ii) a 100% overlap of FBM in the intracellular halves of transmembrane helices, intracellular loops, and Cterminal regions as annotated in the downloaded sequence files. The Ig21 structure from 2J3S is represented by the electrostatic potential on the surface calculated using the program APBS 40 and contoured at ±12kT/e. In Vitro Kinase Assays. The kinase assay reaction conditions included 50 mM Tris (pH 7.5), 10 mM MgCl 2 , 10 μM FLNaIg16−24 as a substrate, and 10, 50, or 200 μM filamin binding peptides (to release autoinhibition), and 500 μM ATP. For each 100 μL reaction, 1000 units of murine PKA (from NEB) was used. Protein phosphorylation was detected by Western blotting using the phospho-Filamin A antibody (see Peptides and Reagents).
Nuclear Magnetic Resonance (NMR) Spectroscopy.
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N-labeled proteins Ig19 and Ig21 were purified, 32 and the HSQC spectra were recorded in a Bruker Avance 600 MHz spectrometer at 30°C. Spectral processing and analysis were conducted using nmrPipe and NMRView. 41 Isothermal Titration Calorimetry (ITC). A MicroCal iTC200 calorimeter from GE Healthcare was used for determining ligand affinities for FLNa Ig repeats. Purified proteins were extensively buffer exchanged into 25 mM sodium phosphate (pH 6.4), 5 mM NaCl, and 1 mM DTT. Peptide ligands were dissolved in the same buffer and estimated as described earlier; 50 μM protein in the sample cell was titrated against 1 mM peptide in the syringe at 30°C in 1 μL increments at a stirring speed of 1000 rpm. The solubility of the α 1D -AR peptide was limited, and hence, this peptide was at an effective concentration of 0.4 mM in the syringe. Affinities were determined by fitting the heat changes to a one-site binding model using the associated Origin package.
Expression of FBM-Containing GPCRs, AT1R, and MAS Constructs and Cell Culture. The cloning of wild-type (WT) MAS with an N-terminal myc tag and establishment of tetracycline/doxycycline-inducible stable cell lines in HEK293 cells were described previously (HEK-MAS). 42 These stable cell lines were maintained in a humidified incubator at 37°C and 5% CO 2 and grown in complete medium (DMEM) supplemented with fetal bovine serum (10%), penicillin/ streptomycin (100 units/mL), blasticidin (5 μg/mL), and hygromycin (300 μg/mL). For experiments, the cells were induced with complete medium containing doxycycline (100 ng/mL) for 26−28 h for the expression of MAS. Uninduced cells were used as negative controls in the experiments. Expression and characterization of HA-tagged rat AT1R (HA-AT1R) in the HEK293 cell line were described previously (HEK-AT1R).
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Co-immunoprecipitation of Filamin with FBM-Containing GPCRs. HEK293 and HEK-AT1R cells were used for these experiments. For the filamin−GPCR interaction experiment, HEK293 and HEK-AT1R cells were serum starved for 4 h. The cells were lysed in Triton X-100 lysis buffer [0.8% Triton X-100, 20 mM Tris-HCl (pH 7.4), 300 mM NaCl, 1 mM EDTA, 20% glycerol, 0.1 mM PMSF, and leupeptin and aprotinin at 10 μg mL −1 each]; 2 mg of total protein was used to immunoprecipitate AT1R using the anti-HA affinity matrix (Roche). Immunoprecipitates were resolved using 8% sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS− PAGE) and immunoblotted for filamin using anti-Filamin A monoclonal antibody MAB1680 (Millipore). Blots were stripped and reblotted for HA to confirm immunoprecipitation of HA-AT1R.
Evaluating Filamin Phosphorylation Levels in Cells Expressing FBM-Containing GPCRs. HEK-AT1R and HEK-MAS cells were used for these experiments. For the analysis of filamin phosphorylation, HEK-AT1R cells were grown until they reached 80−90% confluency. The cells were serum starved for 2 h and were pretreated with either vehicle or AT1R antagonist candesartan (10 μM) for 30 min. Following this, AT1R-expressing cells were treated with either vehicle or agonist angiotensin II (1 μM) for 1 h. Whole cell protein lysates were prepared from these cells in Mammalian Protein Extraction Reagent buffer (M-PER from Thermo Scientific, Rockford, IL) with protease and phosphatase inhibitors. Equal quantities (∼25 μg) of these lysates were separated via 4 to 12% SDS−PAGE and then transferred onto a nitrocellulose membrane for Western blot analysis. The membranes were probed with pFLNa, FLNa, and GAPDH antibodies and suitable near-infrared (IR) dye-conjugated secondary antibodies (LI-COR, Lincoln, NE). The ratios of phospho-FLNa (pFLNa) to FLNa were calculated on the basis of the fluorescence values and expressed as fold increase over uninduced/untreated controls. GAPDH was used as an additional control to confirm equivalent total protein loaded in the lanes. Data for AT1R are presented as an average [mean ± standard error of the mean (SEM)] of two independent experiments (N = 2). Significance levels of an unpaired Student's t test are p < 0.05. The HEK-MAS cells were induced for 24 h with or without 10 μM ARinverse agonist. This was followed by serum starvation of cells for 2 h without any inhibitors or with a combination of 10 μM AR-inverse agonist or 10 μM PKA-inhibitor (H-89) depending on the experimental design. During induction and serum starvation, AR-inverse agonist was added to the HEK-MAS cells to prevent constitutive activation of MAS. Following serum starvation and pretreatment with inhibitors, the cells were treated with 10 μM AR-agonist along with PKA inhibitor H-89 for 1 h. FLNa phosphorylation in whole cell protein lysates was assayed on Western blots as described for HEK-AT1R. Data for MAS are presented as an average (mean ± SEM) of three independent experiments (N = 3). Significance levels of an unpaired Student's t test are p < 0.05.
■ RESULTS

Frequency of FBMs in GPCRs.
In a recent study, 37 we recognized that filamin ligand peptides from integrins and migfilin enhance PKA-mediated phosphorylation of S2152 in filamin by relieving autoinhibition of the Ig21 repeat by Ig20. Because some GPCRs are known to interact with filamin, 13−15 we parsed the literature for GPCR-derived peptides that were reported to bind filamin. The D3 dopamine receptor (D3R) peptide from the ICL3 region was shown to bind Ig19 of filamin. Many such peptides derived from cell adhesion-related proteins bind class A Ig repeats of filamin as reported previously. 32 Similar to these peptides, the D3R peptide increased the rate of PKA-mediated phosphorylation at S2152 in the purified 100 kDa FLNa Ig16−24, a filamin surrogate, as described previously 36, 37 ( Figure 1A ). The effect though was not as pronounced as those of strong binding migfilin, integrin β7, and GP1bα-derived peptides. 37 The stronger ligands relieve autoinhibition more effectively, thereby enhancing S2152 phosphorylation by PKA. The result suggested that D3R not only binds to Ig19 but also may bind to Ig21. 32 We confirmed that this ICL3 peptide from D3 dopamine receptor (D3R) Biochemistry Accelerated Publication binds FLNa Ig19 and Ig21 ( Figure 1B ,C) just as other filamin binding peptides by HSQC NMR spectroscopy. The affinity of the D3R peptide for Ig21 could not be assessed accurately by ITC because of its lower affinity. However, this observation led us to explore the possibility that the presence of FBM sequence in GPCRs might be a conserved feature essential for directly engaging filamin in cells and activating FLNa phosphorylation. We therefore used sequence and structural information about known binders for the class A Ig domain of FLNa including D3R and defined a consensus FBM for GPCRs (see Experimental Procedures and Figure 2) . A bioinformatics screening of the sequences of 824 human GPCRs uncovered conservation of FBMs in the cytoplasmic regions of 116 nonolfactory GPCRs (Table S1 ) and 73 olfactory GPCRs (Table S2) . Of particular significance to the cell biological function of GPCRs is the finding that FBMs were predominantly located in the functionally significant regions of GPCRs, the cytoplasmic tail (Ct) followed by intracellular loop 3 (ICL3). Several novel candidate GPCRs that can potentially engage FLNa with high affinity were found in our search.
We selected AT1R and MAS from this list for experimental verification given their importance in cardiovascular physiology. The FBM in AT1R and MAS is present in the Ct. In the recently determined structure of AT1R, 44 the position of FBM overlaps with the functionally important and structurally flexible "helix 8" region. The α 1D -adrenoreceptor (α 1D -AR) with cardiovascular and neuronal roles was chosen as a representative GPCR with the predicted FBM in ICL3. 45, 46 The ICL3 loop is a very important determinant for G protein activation by GPCRs. To the best of our knowledge, there have been no studies reporting the direct interaction of these three GPCRs with FLNa.
FLNa Ig 21 Binds to Predicted FBMs from AT1R, MAS, and α 1D -AR. FLNa Ig21 is the representative filamin Ig repeat used extensively to test ligand binding. 32, 35 We therefore performed NMR spectroscopy and ITC experiments on the binding of this repeat with the GPCR-derived FBM peptides. Binding of all three FBM peptides to Ig21 resulted in significant changes in the 15 N HSQC spectra ( Figure 3A,C,E) . In the spectra, peaks for G2267, G2270, and S2279 that occupy the top and bottom of the "CD" ligand binding groove showed changes that are typical of high-affinity binders. 32, 36 Hence, these peptides most likely bind in a mode similar to that of the known filamin Ig−peptide complex structures through a β-strand augmentation. ITC experiments estimated the binding affinities of peptide motifs of AT1R, MAS, and α 1D -AR for FLNa Ig21 with K d values of 0.8, 0.3, and 0.8 μM, respectively. These binding affinities are 50−100 times higher than those of the FBM peptides from cell adhesion proteins, the integrins, which are the most common filamin binding proteins in a majority of cell types (see Discussion). The β7 integrin Ct peptide binds Ig21 with a K d of 40 μM. 47 These binding affinities are among the tightest known to bind filamin with the exception of the platelet specific protein, GPIbα, 32 which has an affinity of 0.1 μM.
Given that the filamin−adhesion receptor FBM interaction is tightly coupled to filamin phosphorylation at S2152 by PKA, 37 we tested the effect of these GPCR FBM peptides on FLNa phosphorylation at S2152 in the filamin surrogate, FLNa Ig16− 24, by PKA in an in vitro kinase assay. As expected, binding of these FBM peptides enhanced the rate of phosphorylation of the 100 kDa surrogate of FLNa at S2152 by PKA in vitro (Figure 4 ) like the conventionally known FLNa ligands, integrins, and migfilin. 32 This enhancement of filamin S2152 phosphorylation by high-affinity FBM peptides derived from AT1R, MAS, and α 1D -AR was much more robust than that of the D3R-derived peptide that binds with a lower affinity ( Figure 1A vs Figure 4 ). This observation further emphasizes our premise that tighter binding ligands drive the filamin Ig21 domain conformation toward a PKA compliant state. 32 These findings validate the finding that the predicted FBMs in GPCRs are bona fide functional units and therefore may confer the ability to recruit FLNa to agonist-activated GPCRs in cells. To demonstrate ligand regulation of a native GPCR interaction with filamin in cells, we selected ATIR as a model receptor. Immunoprecipitation of HA-tagged rat AT1R from detergent-solubilized HEK-AT1R cell lysates using an anti-HA monoclonal antibody showed co-immunoprecipitation of endogenous Filamin A (280 kDa) with HA-AT1R (≈78 kDa). HEK cells not expressing HA-AT1R were used as a negative control ( Figure 5A ). Immunoprecipitation of HA-tagged AT1R is shown in the bottom panel ( Figure 5A ). We next examined whether ligandmodulated receptor activity is associated with phosphorylation of filamin in cells. Treatment of the cells with the agonist peptide AngII led to a 5-fold higher level of filamin phosphorylation, and treatment with the inverse agonist, candesartan, reduced the level of filamin phosphorylation to basal levels ( Figure 5B ). Together, these results demonstrate that endogenous Filamin A binds AT1R and agonist activation of AT1R enhances phosphorylation of cellular filamin at S2152, suggesting a direct role for AT1R in actin remodeling through filamin.
Physical and Functional Interaction of MAS with FLNa. We studied MAS to substantiate GPCR-linked filamin phosphorylation results, as MAS is a constitutively active oncogenic GPCR with promiscuous G protein coupling ability. 42 In addition, it contains a bona fide FBM that binds Ig21 with very high affinity as measured by robust biophysical techniques ( Figure 3C,D) . For these studies, we used the tetracycline-inducible system of myc-tagged human MAS expression in HEK293 cells as previously described. 42 We examined functional coupling between MAS and endogenous FLNa in tetracycline-induced cells by monitoring FLNa phosphorylation at S2152. The uninduced cells served as a control. Tetracycline induction of MAS expression alone caused a 7-fold increase in the level of phosphorylation of FLNa ( Figure 6A ). This is not surprising as we and others have reported the high constitutive activity of MAS. 42, 48, 49 FLNa phosphorylation induced by the constitutive activity of MAS was abolished in cells treated with a specific inhibitor of the constitutive activity of MAS, AR-inverse agonist ( Figure 6B ). Treatment of MAS-expressing cells with a specific MAS agonist, AR-agonist, further increased the level of phosphorylation of FLNa 10-fold ( Figure 6A ). Agonist stimulation of cells pretreated with AR-inverse agonist (during induction) resulted in a 9-fold increase in the level of FLNa phosphorylation ( Figure 6B ). Unlike AT1R, MAS activates all major G proteins in cells, including the G s protein-coupled cAMP pathway leading to the activation of PKA. Consistent with this finding, treatment of MAS agonist-activated cells with the PKA inhibitor, H-89, resulted in reversal of the phosphorylated FLNa (pFLNa) levels to constitutive levels ( Figure 6A ). Furthermore, treatment with H-89 decreased the pFLNa levels by 60% in cells pretreated with AR-inverse agonist. These experiments demonstrate that only a part of FLNa phosphorylation in cells by both constitutive and agonist activation of MAS is PKA-dependent. The remaining phosphorylation takes place perhaps by other cellular Ser/Thr kinases.
Experiments depicted in Figures 5 and 6 suggest that the FBM in AT1R and MAS likely adopts a FLNa binding conformation only upon receptor activation. AT1R does not signal constitutively and needs agonist binding to activate the filamin binding mode; however, MAS likely binds filamin constitutively and hence leads to constitutive filamin phosphorylation. These results emphasize that it is the active receptor that mediates filamin phosphorylation by PKA or other cellular S/T kinases. Overall, our data suggest (i) conservation of FBM in GPCRs and (ii) receptor activationdependent phosphorylation of FLNa that is most likely a consequence of FLNa−GPCR interactions. A dagger denotes X-ray structures (chain annotation). A section mark denotes NMR structure. Double daggers denote homologous sequences of integrin β1 and integrin β3, and predicted alignment of dopamine receptor peptides from a previous study. 37 Basic residues are colored blue, acidic residues red, uncharged polar residues green, and hydrophobic residues black. The most conserved residue position is designated 0, and all residues are labeled accordingly (numbering above the alignment). The cartoon of the β-sheet on the top of the alignment depicts the secondary structure adopted by the FLNa ligand in the PDB structures. 
■ DISCUSSION
Impetus for (i) the bioinformatics discovery of FBM in >20% of GPCRs and (ii) experimental validation of GPCRs as bona fide ligands for relieving the autoinhibited state of FLNa is based on our recently reported findings. 37 It was found that phosphorylation of S2152 in filamin was dependent on relieving autoinhibition of Ig20 by engagement of Ig21 by receptors harboring an FBM. Conventionally studied filamin activators were peptides derived from cell adhesion molecules. Migfilin, integrin β7, and GPIbα peptides enhanced PKAmediated filamin phosphorylation in vitro, indicating that functionally diverse ligands can promote filamin phosphorylation. Regulation of the homeostatic equilibrium between FLNa and pFLNa by these conventional activators is known to be critical in cell cytoskeletal dynamics, leading to changes in cell adhesion responses. 33 Though there is literature about filamin−GPCR interaction at the functional and biochemical level, broad generalizations were obscure at best. The D2R and D3R peptides were the most clearly recognized class A filamin binders. 38, 32 The extent of the involvement of FBMs in GPCRs, the superfamily of cell surface receptors for conducting FLNamediated cytoskeletal signaling, is a major gap in the current knowledge base. To bridge this gap, we report here for the first time a consensus FBM in GPCRs and identify several GPCRs that contain FBMs in their intracellular regions. We noticed several important GPCRs that are part of this select GPCR list (Table S1 ). For example, lysophosphatidic acid treatment was reported to increase the level of FLNa phosphorylation in previous studies. 50 However, the role of any particular receptor in the process was not addressed. Our predicted hits contain lysophosphatidic acid receptor 2, suggesting a possible role for this receptor in directly engaging FLNa. Similarly, kinin treatment was shown to alter filamin translocation in endothelial cells. 51, 52 The roles of B1 and B2 bradykinin receptors (B1R and B2R) were mentioned in this process, but never proven. In our predictions, we identified B2R to contain the FBM, and most interestingly, a pairwise sequence alignment between B1R and B2R reveals a gap in the sequence of B1R at the homologous region spanning the entire length of the FBM, thus providing evidence of the role of B2R but not B1R in the process. Similar, differences in the FBM regions were seen in neuropeptide FF receptors 1 and 2 and dopamine receptors.
Along with the known filamin binders such as dopamine receptors, we also identified several important GPCRs that respond to serotonin, acetylcholine, opioids, angiotensin, chemokines, eicosanoids, and fatty acid ligands. Our list also included the recently identified CXCR4 FBM as a positive hit, although the FBM in this receptor spans both the cytoplasmic and transmembrane regions. The list also has several orphan, olfactory, and taste receptors. Few of the GPCRs that were previously reported to interact with filamin are absent from our list. This is expected as in this study we attempted to define FBM for only class A repeats in FLNa with very strict criteria. We speculate that via expansion of the definition of FBM to include proteins binding to (1) repeats other than class A and (2) other filamin isoforms (B and C), the predicted list of GPCRs for interacting with filamin would be substantially large. More crystal structures of peptide motifs with FLN Ig domains would further aid in improving these predictions. Because our predictions are based on a limited number of crystal structures with peptides, the potential for false positive hits as well as missing more potent filamin binding GPCRs cannot be excluded. Our search criteria were stringent, and all 12 residues needed for filamin engagement were filtered to be part of cytoplasmic regions (see Experimental Procedures).
From the predicted list, we picked three different GPCRs, MAS, AT1R, and α 1D -AR, which are important in cardiovascular physiology, for further experimental validation. These three receptor peptides have no known topological constraints with respect to binding filamin. Using NMR and ITC, we show unambiguous tight binding of the FBM peptides to FLNa Ig21. The affinities in the nanomolar range determined by ITC are extremely rare for filamin binders. Only the platelet specific GP1bα receptor peptide shows a binding tighter than those of the three GPCRs listed above. 32 Compared to integrins, 47 the three GPCR peptides tested here have 50−100-fold higher affinity and are likely to be very biologically potent. We are not aware of any report of GPCR peptides showing such high affinity by ITC for any known GPCR binder. The only study we came across is the binding of the cannabinoid receptor peptide to β-arrestin with an affinity of 2 μM. 54 Furthermore, the bound FBM peptides promoted rapid phosphorylation of FLNa at S2152 under in vitro conditions, validating our biophysical studies.
In strong support of the in vitro findings that ligand binding induces FLNa phosphorylation at S2152, we observed robust 
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Accelerated Publication phosphorylation of FLNa on the S2152 site in cells expressing the FBM-containing GPCRs, AT1R and MAS. We note that unlike AT1R there was strong basal/constitutive (agonistindependent) filamin phosphorylation induced by MAS. This was expected as the cAMP levels are significantly higher at basal levels in MAS-expressing cells, 42, 48 causing PKA activation that could be inhibited by H-89. To tease out acute or short-term signaling effects of MAS and its consequences in cells, we inhibited constitutive activity by adding AR-inverse agonist to the cells at the time of induction. This allowed us to demonstrate the receptor activation-dependent increase in the level of phosphorylation of FLNa. The lack of robust reagents prevented us from extending our results to α 1D -AR.
Intriguingly, only 60% of the increase in pFLNa in MASexpressing cells was inhibited by H-89, suggesting the involvement of kinases other than PKA in the process. 12 The residual component of pFLNa is most likely generated by kinases that are activated in the cells by other G protein pathways. 50, 55 Constitutive or ligand-dependent activation of AT1R and MAS likely introduces conformational changes in the FBM that is suitable for FLNa engagement. Thereby, AT1R and MAS directly bind to Ig21 and prevent autoinhibition of FLNa Ig21 by Ig20. The resultant GPCR-bound FLNa becomes a substrate for kinases (not limited to PKA) that are active in cells through signaling or independently by other mechanisms. Ser/Thr kinase such as ribosomal S6 kinase activated upon AT1R activation is a known FLNa phosphorylating kinase. 50, 56 Overall, kinases increase pFLNa levels in the cells and likely promote cytoskeletal assembly. Taken together, these two receptors seem to couple with filamin during or immediately after agonist activation. Antagonist binding prevents phosphorylation of filamin with both of these receptors, validating our agonist data. The details of this process most likely involve a helix/loop to β-strand change in the Ct regions of the receptors that transiently enhances filamin binding only in the presence of the agonists. The cytoplasmic regions of GPCR also bind β-arrestin following agonist activation. In a previous proteomic study, FLNa was shown to interact with β-arrestin. 57 Whether β-arrestin assembly plays a role in the interaction of FLNa with GPCRs and subsequent FLNa phosphorylation is currently unknown and is an interesting area for future research. The enhanced engagement of filamin to an activated receptor is seen in some recent work though not recognized as such. 53 Our model provides a molecular explanation of the previously reported G protein signaling-mediated filamin phosphorylation in which direct FLNa−GPCR interaction was not observed (Figure 7) . 50, 58 This is the first report to demonstrate filamin phosphorylation tied to the activation status of GPCRs. Filamin phosphorylation has been linked to defects in neuronal migration, actin binding, and cytoplasmic localization 59 through guanine exchange factor ARFGEF2. Interestingly, agonistdependent filamin phosphorylation appears not to be limited to G s -coupled GPCRs as observed in this study and in other reports. This implies that a cAMP-independent activation of PKA may play a role in case of those GPCRs. Evidence of such a phenomenon is available for mouse AT1A and endothelin-1 receptors. 60 Filamin phosphorylation might reposition filamin with respect to the plasma membrane because of charge repulsion, and in this new microenvironment, its binding partners may change, thereby bridging a different set of proteins. Filamin seems necessary for optimal coupling of G protein to D3R, 14 and dopamine treatment has been shown to reduce the extent of binding of filamin to the receptor. 61 Filamin has been shown to form a complex with the β-arrestin and GPCR in at least three cases, i.e., D3R, 61 AT1R, and muscarinic M1 receptor (M1MR). 62 The Ig22 domain of filamin was characterized as the most likely docking site for β-arrestin, and a β-arrestin−FLNa−receptor complex regulates ERK activation and membrane ruffling. 62 However, direct binding of filamin to the AT1R and M1MR was not considered a mechanism in the previous work. However, our bioinformatics search identified a potetnial FBM in M1MR (Table S1 ). More structural information acquired by NMR or crystallography will help in robust hypothesis generation to unravel the precise molecular details. In AT1R and MAS, the FBM is part of the cytoplasmic helix 8 that plays a crucial but imprecisely defined role in various GPCRs. 63 In AT1R and other GPCRs, this region was also shown and/or predicted to bind to tubulin. 64 In most crystal structures of GPCRs, this region is a helix, part of a helix, or unstructured or has missing electron density (PDB entries 4DAJ, 2R4S, 3ODU, 3VW7, and 4YAY). 
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We envisage an agonist/antagonist-dependent conformational switch in this region of many GPCRs that facilitate filamin engagement. Given our data, the role that filamin and its phosphorylation plays in GPCR function will have to be pursued with more vigor.
On a final note, the class A Ig repeats of filamin mainly bind unstructured segments of membrane receptors. It is also interesting to note that the cytoplasmic regions, especially the ICL3 and Ct regions of GPCRs, are highly variable in length and are predicted to be intrinsically disordered. 65, 66 Given that >30% of the eukaryotic proteomes contains disordered segments, 67−69 it is tempting to speculate that filamin may bind many more proteins than currently recognized. Moreover, Filamin Ig repeats have expanded in number during eukaryotic evolution, 70 and this may have some correlation with the expansion of disordered segments in many signaling proteins. There is speculation in the literature that millions of such disordered motifs may exist, 71 and large proteins like filamin with their ability to bind these motifs may have co-evolved. FLNa is also alternately spliced, resulting in an isoform that lacks autoinhibtion and the S2152 phosphorylation site. 72, 73 Filamin isoform switching may therefore regulate both mechanistic and signaling outcomes during animal development.
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